Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Faster European drug reviews

Executive Summary

U.K.'s National Institute for Clinical Excellence announces plans to expedite reviews. NHS division is "in discussion with the Department of Health over proposals for a revised process allowing more rapid appraisal of important new drugs." The proposals were evaluated by NICE's board at a meeting Sept. 21. The European Medicines Agency has also proposed its new framework for Scientific Advice & Protocol Assessment, which "provides for earlier and greater involvement of internal assessors and external experts." Comments are due by Nov. 22. EMEA projects the new review procedure could reduce response time from 100 days to 70 days (1"The Pink Sheet" July 11, 2005, p. 26)...

You may also be interested in...



EMEA Working To Substantially Shorten Scientific Advice Response Time

The European Medicines Agency is developing a new scientific advice procedure aimed at shortening the timeframe for providing drug development feedback to manufacturers

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Topics

UsernamePublicRestriction

Register

PS046378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel